BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 28347512)

  • 21. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 24. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
    Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
    Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
    Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
    Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
    Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
    J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
    Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma.
    Arabi H; Guan H; Kumar S; Cote M; Bandyopadhyay S; Bryant C; Shah J; Abdul-Karim FW; Munkarah AR; Ali-Fehmi R
    Gynecol Oncol; 2009 May; 113(2):153-8. PubMed ID: 19275958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
    Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
    Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer.
    Pagnotti GM; Atkinson RM; Romeiser J; Akalin A; Korman MB; Shroyer KR
    Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):515-522. PubMed ID: 29189263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
    An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
    Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
    Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
    JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma.
    Modica I; Soslow RA; Black D; Tornos C; Kauff N; Shia J
    Am J Surg Pathol; 2007 May; 31(5):744-51. PubMed ID: 17460459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
    Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
    Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.